Sernova Biotherapeutics Inc (TSX:SVA)
Canada · Delayed Price · Currency is CAD | Market Cap | 41.54M -29.7% |
| Revenue (ttm) | n/a |
| Net Income | -11.91M |
| EPS | -0.04 |
| Shares Out | 377.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 65,264 |
| Open | 0.1200 |
| Previous Close | 0.1150 |
| Day's Range | 0.1100 - 0.1200 |
| 52-Week Range | 0.1000 - 0.2000 |
| Beta | 0.64 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 11, 2026 |
About Sernova Biotherapeutics
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc ... [Read more]
Financial Performance
Financial StatementsNews
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focus...
Sernova Biotherapeutics Registration statement: Q2 2026
Sernova Biotherapeutics filed a registration statement on June 11, 2026, providing details about a securities offering with the SEC.
Sernova Biotherapeutics Registration statement: Q2 2026
Sernova Biotherapeutics filed a registration statement on June 11, 2026, providing details about a securities offering with the SEC.
Sernova Biotherapeutics Announces Closing of Recently Approved Financings
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) (XETRA: PSHO) ("Sernova" or the "Company"), a leading regene...
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 9, 2026) - Sernova Biotherapeutics Inc. (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative med...
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 24, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC Pink: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative me...
Sernova Biotherapeutics Registration statement: Q1 2026
Sernova Biotherapeutics filed a registration statement on March 13, 2026, providing details about a securities offering with the SEC.
Sernova Biotherapeutics Registration statement: Q1 2026
Sernova Biotherapeutics filed a registration statement on March 13, 2026, providing details about a securities offering with the SEC.
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 4, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine...
Sernova Biotherapeutics Announces Warrant Amendments
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company ...
Sernova Biotherapeutics Registration statement: Q4 2025
Sernova Biotherapeutics filed a registration statement on December 19, 2025, providing details about a securities offering with the SEC.
Sernova Biotherapeutics Registration statement: Q4 2025
Sernova Biotherapeutics filed a registration statement on December 19, 2025, providing details about a securities offering with the SEC.
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focus...
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
TORONTO and BOSTON - September 22, 2025 - The Newswire — Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) a leading regenerative medicine company focused on developing it...
Sernova Biotherapeutics Registration statement: Q3 2025
Sernova Biotherapeutics filed a registration statement on September 14, 2025, providing details about a securities offering with the SEC.
Sernova Biotherapeutics Registration statement: Q3 2025
Sernova Biotherapeutics filed a registration statement on September 14, 2025, providing details about a securities offering with the SEC.
Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes
Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova's Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes Tegoprubart to be Used as Immunosuppres...
Sernova Biotherapeutics Registration statement: Q2 2025
Sernova Biotherapeutics filed a registration statement on June 12, 2025, providing details about a securities offering with the SEC.
Sernova Biotherapeutics Registration statement: Q2 2025
Sernova Biotherapeutics filed a registration statement on June 12, 2025, providing details about a securities offering with the SEC.
Sernova Appoints Jonathan Rigby as Interim Chair
LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cel...
Chair of Sernova Biotherapeutics Resigns
LONDON, Ontario and BOSTON, May 26, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell...
Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes
LONDON, Ontario and BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell...
Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes
Clinical Study on Track to Meet its Primary and Secondary Endpoints Data Demonstrate That Metabolic Measures Improve with Cumulative Quantities of Transplanted Donor Islets Data Demonstrate Islet Engr...
Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans
LONDON, Ontario and BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it's C...
Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med
LONDON, Ontario and BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company, today announced that the Co...